Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Nutrition Reports
Erschienen in: Current Nutrition Reports 4/2013

01.12.2013 | Diabetes and Obesity (A Sánchez-Villegas, Section Editor)

Evidence Linking Mental Health with Obesity and Metabolic Syndrome: The Role of Inflammation

verfasst von: Alanna A. Morris, Viola Vaccarino

Erschienen in: Current Nutrition Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of the metabolic syndrome has risen rapidly within the background of the global obesity epidemic, and estimates suggest that this number may continue to rise. A chronic low-grade inflammatory state is associated with the presence of the metabolic syndrome, reflecting increased production of proinflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), as well as the adipokines leptin and adiponectin. Inflammation is being increasingly recognized as a mechanism that may contribute to the pathogenesis of mental health disorders, because it has been documented that peripheral hormonal and inflammatory signals can access the brain and activate relevant cell types that serve to amplify central inflammatory responses. Inflammation related to obesity may be the mechanism underlying the association between metabolic syndrome and mental health disorders.
Literatur
1.
Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of Obesity in the United States, 2009–2010. NCHS Data Brief No. 82;2013.
2.
Ervin RB. Prevalence of metabolic syndrome among adults 20 years of Age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Rep. 2009;13:1–7.
3.
Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
4.
Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, Participants ftC. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004;109:433–8.PubMedCrossRef
5.
•• Mottillo S, Filion KB, Genest J, et al. The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2010;56:1113–32. This article presents a current analysis of MetS with CV risk and all-cause mortality in >951,083 patients. PubMedCrossRef
6.
Gami AS, Witt BJ, Howard DE, et al. Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death: A Systematic Review and Meta-Analysis of Longitudinal Studies. J Am Coll Cardiol. 2007;49:403–14.PubMedCrossRef
7.
8.
Bays HE, Gonzalez-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6:343–68.PubMedCrossRef
9.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808.PubMed
10.
Despres J-P. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006;38:52–63.PubMedCrossRef
11.
• Neeland IJ, Ayers CR, Rohatgi AK, et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity 2013;21(9):439–47. This article presents important differences in the inflammatory and adverse metabolic profiles of visceral versus subcutaneous adipose.
12.
Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland Coronary Prevention Study. Circulation. 2003;108:414–9.PubMedCrossRef
13.
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–7.PubMedCrossRef
14.
Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost. 2006;95:511–8.PubMed
15.
Volpato S, Guralnik JM, Ferrucci L, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the Women's Health and Aging Study. Circulation. 2001;103:947–53.PubMedCrossRef
16.
• Schnabel RB, Yin X, Larson MG, et al. Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol. 2013;33:1728–33. This article examined 11 established and novel biomarkers of inflammation and oxidative stress in relation to incident major CVD and mortality in the Framingham Heart Study.PubMedCrossRef
17.
Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity. 2006;14:2127–31.PubMedCrossRef
18.
Langenberg C, Bergstrom J, Scheidt-Nave C, Pfeilschifter J, Barrett-Connor E. Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers. Diabetes Care. 2006;29:1363–9.PubMedCrossRef
19.
Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006;83:461S–5S.PubMed
20.
Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96:939–49.PubMedCrossRef
21.
Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1–16.PubMedCrossRef
22.
•• Morris AA, Ahmed Y, Stoyanova N, et al. The association between depression and leptin is mediated by adiposity. Psychosom Med. 2012;74:483–8. This article found that the relationship between leptin and depression appears to be mediated by adipostiy, and showed a clinical role for both leptin resistance as well as insufficiency in depressive symptoms.
23.
Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology and pathophysiology – emerging clinical applications. Nat Rev Endocrinol. 2006;2:318–27.
24.
Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998;12:57–65.PubMed
25.
Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105:2893–8.PubMedCrossRef
26.
Ouedraogo R, Gong Y, Berzins B, et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest. 2007;117:1718–26.PubMedCrossRef
27.
•• Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011;25:181–213. This article provides a cellular/molecular model of the role of immune factors in behavioral and neural plasticity in physiological and inflammatory conditions.
28.
Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.PubMedCrossRef
29.
Hirschfeld R. Depression epidemiology and its treatment evolution. J Clin Psychiatry 2012;73(10):e29.
30.
The World Health Organization. The global burden of disease: 2004 update, Table A2: burden of disease in DALYs by cause, sex and income group in WHO regions, estimates for 2004. Geneva, Switzerland: WHO; 2008.
31.
• Daly M. The relationship of C-reactive protein to obesity-related depressive symptoms: a longitudinal study. Obesity. 2013;21:248–50. This article explores longitudinal associations between obesity, inflammation, and depressive symptoms. PubMedCrossRef
32.
•• Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220–9. This article examines the longitudinal bidirectional associations between obesity and depressive symptoms in >58,000 patients. PubMedCrossRef
33.
Capuron L, Su S, Miller AH, et al. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry. 2008;64:896–900.PubMedCrossRef
34.
Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the third national health and nutrition examination survey. Psychosom Med. 2004;66:316–22.PubMedCrossRef
35.
Dunbar JA, Reddy P, Davis-Lameloise N, et al. Depression: an important comorbidity with metabolic syndrome in a general population. Diabetes Care. 2008;31:2368–73.PubMedCrossRef
36.
• Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman ATF, Penninx BWJH. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol Psychiatry. 2013;18:692–9. This article explores important differences in inflammatory markers, diurnal cortisol variations, and MetS components in patients with melancholic versus atypical depression. PubMedCrossRef
37.
Vaccarino V, McClure C, Johnson BD, et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosom Med. 2008;70:40–8.PubMedCrossRef
38.
Pan A, Keum N, Okereke OI, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care. 2012;35:1171–80.PubMedCrossRef
39.
Felger JC, Lotrich FE. Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications. Neuroscience 2013;246:199–229.
40.
Lotrich FE. Gene-environment interactions in geriatric depression. Psychiatr Clin N Am. 2011;34:357–76.CrossRef
41.
Charney DS. Monamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59:11–4.PubMed
42.
Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31:464–8.PubMedCrossRef
43.
Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001;49:391–404.PubMedCrossRef
44.
Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732–41.PubMedCrossRef
45.
• Hickman R, Khambaty T, Stewart J. C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004. J Behav Med 2013;epub 30 Apr 2013:1-9. This article examines CRP levels in adults from the NHANES cohort with atypical, nonatypical and no depression.
46.
Elovainio M, Keltikangas J, Auml, et al. Depressive symptoms and C-reactive protein: The Cardiovascular Risk in Young Finns Study. Psychol Med. 2006;36:797–805.PubMedCrossRef
47.
Azar R, Nolan R, Stewart D. Listening to the heart-brain talk: persistent depressive symptoms are associated with hsCRP in apparently healthy individuals at high risk for coronary artery disease. Eur J Prev Cardiol. 2012;19:857–63.PubMedCrossRef
48.
Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med. 2003;65:347–56.PubMedCrossRef
49.
Gimeno D, Kivimaki M, Brunner EJ, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2009;39:413–23. doi:10.​1017/​S003329170800372​3.PubMedCrossRef
50.
Elovainio M, Aalto A-M, Kivimaki M, et al. Depression and C-reactive protein: population-based health 2000 study. Psychosom Med. 2009;71:423–30.PubMedCrossRef
51.
• Janicki Deverts D, Cohen S, DiLillo VG, et al. Depressive symptoms, race, and circulating C-reactive protein: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Psychosom Med. 2010;72:734–41. This article explores race-based differences in the longitudinal association between CRP and depressive symptoms. CrossRef
52.
• Morris AA, Zhao L, Ahmed Y, et al. Association Between Depression and Inflammation‚ Differences by Race and Sex: The META-Health Study. Psychosom Med. 2011;73:462–8. This article explores race- and gender-based differences in the association between CRP and depressive symptoms.PubMedCrossRef
53.
Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. 2013;11:1–14.CrossRef
54.
Su S, Miller AH, Snieder H, et al. Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged Men: the Twins Heart Study. Psychosom Med. 2009;71:152–8.PubMedCrossRef
55.
Sonikian M, Metaxaki P, Papavasileiou D, et al. Effects of interleukin-6 on depression risk in dialysis patients. Am J Nephrol. 2010;31:303–8.PubMedCrossRef
56.
Bremmer M, Beekman A, Deeg D, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. 2008;106:249–55.PubMedCrossRef
57.
Pace TWW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163:1630–3.PubMedCrossRef
58.
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.PubMedCrossRef
59.
• Duivis HE, Vogelzangs N, Kupper N, de Jonge P, Penninx BWJH. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: Findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology 2013;38(9):1573–85. This article explores the associatin of both cognitive and somatic symptoms of depression and anxiety with CRP, IL-6 and TNF-α.
60.
Einvik G, Vistnes M, Hrubos-Strom H, et al. Circulating cytokine concentrations are not associated with major depressive disorder in a community-based cohort. Gen Hosp Psychiatry. 2012;34:262–7.PubMedCrossRef
61.
• Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57. This meta-analysis examines the association between depression in 24 studies and multiple cytokines, including IL-6, TNF-α, IL-1β, IL-4, IL-2, IL-8, IL-10, and IFN-γ.PubMedCrossRef
62.
•• Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist Infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41. This trial examines whether baseline inflammatory biomarkers predict response to use of the TNF-α antagonist infliximab for treatment-resistant depression. PubMedCrossRef
63.
Zeugmann S, Quante A, Heuser I, Schwarzer R, Anghelescu I. Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. J Clin Psychiatry. 2010;71:1007–16.PubMedCrossRef
64.
Jow GM, Yang TT, Chen CL. Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord. 2006;90:21–7.PubMedCrossRef
65.
Kraus T, Haack M, Schuld A, Hinze-Selch D, Pollmacher T. Low leptin levels but Norma body mass indices in patients with depression or schizophrenia. Neuroendocrinology. 2001;73:243–7.PubMedCrossRef
66.
Antonijevic IA, Murck H, Frieboes RM, Horn R, Brabant G, Steiger A. Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res. 1998;32:403–10.PubMedCrossRef
67.
Gecici O, Kuloglu M, Atmaca M, et al. High serum leptin levels in depressive disorders with atypical features. Psychiatry Clin Neurosci. 2005;59:736–8.PubMedCrossRef
68.
• Chirinos D, Goldberg R, Gellman M, et al. Leptin and its Association with Somatic Depressive Symptoms in Patients with the Metabolic Syndrome. Ann Behav Med 2013;46(1):31–9. This study explored the associatin of leptin with somatic and cognitive symptoms of depression.
69.
Lehto SM, Huotari A, Niskanen L, et al. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand. 2010;121:209–15.PubMedCrossRef
70.
Leo R, Di Lorenzo G, Tesauro M, et al. Decreased plasma adiponectin concentration in major depression. Neurosci Lett. 2006;407:211–3.PubMedCrossRef
71.
• Cizza G, Nguyen VT, Eskandari F, et al. Low 24-hour adiponectin and high nocturnal leptin concentrations in a case control study of community-dwelling premenopausal women with major depression: The P.O.W.E.R. Study. J Clin Psychiatry. 2010;71:1079–87. This article examines the association of adipokines and HPA-axis activation with depression severity.PubMedCrossRef
72.
• Hood KK, Lawrence JM, Anderson A, et al. Metabolic and inflammatory links to depression in youth with diabetes. Diabetes Care. 2012;35:2443–6. This article examines eight metabolic and inflammatory markers in youth with type 1 and type 2 diabetes. PubMedCrossRef
73.
De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15–22.
74.
De Hert M, Van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006;2:1–10.CrossRef
75.
De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101:295–303.PubMedCrossRef
76.
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601.
77.
Na K-S, Jung H-Y, Kim Y-K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2012;epub 1 November 2012. doi:10.​1016/​j.​pnpbp.​2012.​10.​022.
78.
Miller BJ, Culpepper N, Rapaport MH. C-Reactive Protein Levels in Schizophrenia. Clinical Schizophrenia and Related Disorders 2013;epub 21 February 2013. doi:10.​3371/​CSRP.​MICU.​020813.
79.
Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is elevated in schizophrenia. Schizophr Res. 2013;143:198–202.PubMedCrossRef
80.
Sasayama D, Wakabayashi C, Hori H, et al. Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients. J Psychiatr Res. 2011;45:1439–44.PubMedCrossRef
81.
Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47:401–6.PubMed
82.
Zakharyan R, Petrek M, Arakelyan A, Mrazek F, Atshemyan S, Boyajyan A. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens. 2012;80:136–42.PubMedCrossRef
83.
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663–71.PubMedCrossRef
84.
Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37:1901–11.PubMedCrossRef
85.
Gregoor JG, van der Weide J, Loovers HM, van Megen HJGM, Egberts TCG, Heerdink ER. Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics. 2011;12:919–23.PubMedCrossRef
86.
Gregoor JG, van der Weide J, Mulder H, et al. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol. 2009;29:21–5.PubMedCrossRef
87.
Hanssens L, van Winkel R, Wampers M, et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res. 2008;106:308–14.PubMedCrossRef
88.
Chen P-Y, Huang M-C, Chiu C-C, Liu H-C, Lu M-L, Chen C-H. Association of plasma retinol-binding protein-4, adiponectin, and high molecular weight adiponectin with metabolic adversities in patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:1927–32.CrossRef
89.
Bai YM, Chen TT, Yang W-S, et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study. Schizophr Res. 2009;111:1–8.PubMedCrossRef
90.
Kowalski J, Blada P, Kucia K, Madej A, Herman ZS. Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res. 2001;50:169–75.PubMedCrossRef
91.
Contreras-Shannon V, Heart DL, Paredes RM, et al. Clozapine-Induced Mitochondria Alterations and Inflammation in Brain and Insulin-Responsive Cells. PLoS One. 2013;8:1–10.CrossRef
92.
Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res. 1997;26:221–5.PubMedCrossRef
93.
Meyer JM, McEvoy JP, Davis VG, et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry. 2009;66:1013–22.PubMedCrossRef
94.
Skilton MR, Moulin P, Terra J-L, Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry. 2007;62:1251–7.PubMedCrossRef
95.
Herva A, Rasanen P, Miettunen J, et al. Co-occurrence of metabolic syndrome with depression and anxiety in young adults: the northern Finland 1966 birth cohort study. Psychosom Med. 2006;68:213–6.PubMedCrossRef
96.
Takeuchi T, Nakao M, Nomura K, Yano E. Association of metabolic syndrome with depression and anxiety in Japanese men. Diabetes Metab. 2009;35:32–6.PubMedCrossRef
97.
de Winter CF, Hermans H, Evenhuis HM, Echteld MA. Associations of symptoms of anxiety and depression with diabetes and cardiovascular risk factors in older people with intellectual disability. Journal of Intellectual Disability Research 2013;epub 30 Apr 2013. doi:10.​1111/​jir.​12049.
98.
Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism. 2002;51:1573–7.PubMedCrossRef
99.
Whittaker KS, Krantz DS, Rutledge T, et al. Combining psychosocial data to improve prediction of cardiovascular disease risk factors and events: the national heart, lung, and blood institute sponsored Women's ischemia syndrome evaluation study. Psychosom Med. 2012;74:263–70.PubMedCrossRef
100.
Liukkonen T, Rasanen P, Jokelainen J, et al. The association between anxiety and C-reactive protein (CRP) levels: results from the Northern Finland 1966 Birth Cohort Study. Eur Psychiatry. 2011;26:363–9.PubMedCrossRef
101.
Vogelzangs N, Beekman ATF, de Jonge P, Penninx BWJH. Anxiety disorders and inflammation in a large adult cohort. Translational Psychiatry 2013;3:e249.
102.
Pitsavos C, Panagiotakos D, Papageorgiou C, Tsetsekou E, Soldatos C, Stefanadis C. Anxiety in relation to inflammation and coagulation markers, among healthy adults : the ATTICA study. Atherosclerosis. 2006;185:320–6.PubMedCrossRef
103.
Copeland WE, Shanahan L, Worthman C, Angold A, Costello EJ. Generalized anxiety and C-reactive protein levels: a prospective, longitudinal analysis. Psychol Med. 2012;42:2641–50.PubMedCrossRef
104.
Capuron L, Poitou C, Machaux-Tholliez D, et al. Relationship between adiposity, emotional status and eating behaviour in obese women: role of inflammation. Psychol Med. 2011;41:1517–28.PubMedCrossRef
105.
Metadaten
Titel
Evidence Linking Mental Health with Obesity and Metabolic Syndrome: The Role of Inflammation
verfasst von
Alanna A. Morris
Viola Vaccarino
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Nutrition Reports / Ausgabe 4/2013
Elektronische ISSN: 2161-3311
DOI
https://doi.org/10.1007/s13668-013-0054-2

Weitere Artikel der Ausgabe 4/2013

Current Nutrition Reports 4/2013 Zur Ausgabe

Cardiovascular Disease (L Djoussé, Section Editor)

Dietary Cholesterol and Plasma Lipoprotein Profiles: Randomized Controlled Trials

Invited Commentary

The Marketing of Dietary Supplements: A Canadian Perspective

Cardiovascular Disease (L Djoussé, Section Editor)

Effects of Dark Chocolate and Cocoa Products on Endothelial Function: A Meta-Analysis

Public Health and Translational Medicine (PW Franks, Section Editor)

Systems Epidemiology: A New Direction in Nutrition and Metabolic Disease Research

Public Health and Translational Medicine (PW Franks, Section Editor)

Maternal Nutrition and Epigenetics in Early Life

Diabetes and Obesity (A Sánchez-Villegas, Section Editor)

Role of Diet and Diet Interventions in Diabetic Patients: Physiological and Metabolic Changes and Reduction in Morbidity and Mortality

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise